Michael Morgan, PhD

Title(s)Postdoctoral Scholar, Physical Therapy
SchoolSchool of Medicine
Address1001 Potrero Avenue
San Francisco CA 94110
Phone415-341-3533
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Discovery of a lead series of potent benzodiazepine 5-HT2C receptor agonists with high selectivity in functional and binding assays. Bioorg Med Chem Lett. 2020 03 01; 30(5):126929. Ren A, Zhu X, Feichtinger K, Lehman J, Kasem M, Schrader TO, Wong A, Dang H, Le M, Frazer J, Unett DJ, Grottick AJ, Whelan KT, Morgan ME, Sage CR, Semple G. PMID: 31952960.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    2. Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase. EMBO J. 2018 12 14; 37(24). Muñoz IM, Morgan ME, Peltier J, Weiland F, Gregorczyk M, Brown FC, Macartney T, Toth R, Trost M, Rouse J. PMID: 30266825.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    3. Pharmacokinetics and Tolerability of Lorcaserin in Special Populations: Elderly Patients and Patients with Renal or Hepatic Impairment. Clin Ther. 2017 Apr; 39(4):837-848.e7. Christopher RJ, Morgan ME, Tang Y, Anderson C, Sanchez M, Shanahan W. PMID: 28365033.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    4. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring). 2009 Mar; 17(3):494-503. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR, APD356-004 Study Group . PMID: 19057523.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    5. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats. Drug Metab Dispos. 2002 May; 30(5):479-82. Savolainen J, Edwards JE, Morgan ME, McNamara PJ, Anderson BD. PMID: 11950774.
      View in: PubMed   Mentions: 9     Fields:    Translation:Animals